Testicular Cancer

What is testicular cancer?

Testicular cancer is cancer in one or both testicles. It usually occurs in young men and, if detected early, responds to treatment well. It is one of the most common cancers in young men between the ages of 15 and 34. The disease also occurs in other age groups as well and is often found by men themselves. This year 8,010 cases of testicular cancer will be diagnosed in the United States, and about 390 men will die of the disease. It is one of the most curable forms of cancer, with over 90% of cases cured.

What causes testicular cancer?

The cause of testicular cancer is unknown. Age is the most common risk factor, and a family history of testicular cancer increases the risk. If a patient has the disease, there is an increased risk that one or more of his brothers will also develop it. Some studies have indicated that miners, oil and gas workers, leather workers, food and beverage processing workers, janitors, firefighters, and utility workers have elevated risk of developing testicular cancer. An increased risk is also linked to an unusual condition that causes a proliferation of moles on the back, chest, belly, and face. Men infected with HIV (human immunodeficiency virus) have an increased risk. Men who have been cured of cancer in one testicle have an increased risk (about 3 to 4%) of getting cancer in the other testicle. White Americans are 5 to 10 times more likely to get testicular cancer than African American men, and whites have more than twice the risk of Asian American men.

How is testicular cancer diagnosed?

Testicular cancer can cause several symptoms, including a lump in either testicle, enlargement of a testicle, a feeling of heaviness in the scrotum, a dull ache in the lower abdomen or the groin, a sudden collection of fluid in the scrotum, pain or discomfort in a testicle or in the scrotum, or enlargement or tenderness of the breasts. Although these symptoms can be caused by other conditions, early diagnosis of testicular cancer is very important for a man’s chance for complete recovery.

The testicles have many different kinds of cells which may develop into one or more types of cancer. The three main types of testicular cancer are germ cell tumors, stromal tumors and secondary testicular tumors.

  • germ cell tumors - the most common type (over 9 out of 10 cases) of testicular cancer, germ cell tumors begin in the cells that make sperm. Most germ cell cancers begin as carcinoma in situ (CIS), a cancer that is not invasive (has not spread from where it started). It usually takes about five years for CIS to become the invasive form of germ cell cancer. Germ cell cancers are divided into two types: seminomas and nonseminomas. Seminomas (about 40% of cases) start from the sperm-producing germ cells of the testicle. Nonseminomas (choriocarcinoma, embryonal carcinoma, teratoma, and yolk sac tumors) tend to develop earlier in life than seminomas and are often found in men between their late teens and early forties.

  • stromal tumors – tumors that begin in the cells that make hormones and in the supportive tissues (stroma) of the testicles. These tumors are often benign and do not spread beyond the testicle; however, when stromal cell tumors spread to other parts of the body, they have a poor prognosis because they do not respond well to treatments.

  • secondary testicular tumors – tumors that start in another organ and then spread to the testicle. Among men over 50, secondary testicular tumors are more common that tumors that begin in the testicle. The prognosis depends on the type and stage of the original cancer.


Examination of the testicles is the most common test to find testicular cancer.

  • physical examination of the scrotum

  • medical history

  • chest x-ray

  • blood and urine tests

  • biopsy


Once testicular cancer has been diagnosed, prognosis (chance of recovery) and treatment options depend on the stage of the cancer (whether it is contained in the testicles or has spread to other parts of the body). Doctors use many diagnostic tools to determine the stage, including:

  • computed tomography (CT or CAT scan) or PET scan

  • lab tests for tumor markers to help determine the type of testicular cancer

  • surgery to remove lymph nodes deep in the abdomen


What are the treatment options?

There are different types of treatment for patients with testicular cancer. The three main standard methods are surgery, radiation therapy, and chemotherapy. The doctor may choose to use just one or a combination. Other treatments are being tested through clinical trials.

  • surgery – used to remove the testicle and sometimes lymph nodes in the abdomen. Tumors that have spread to other parts of the body may be partly or entirely removed as well.

  • radiation therapy – also called x-ray therapy, radiotherapy, cobalt treatment or irradiation, high-energy x rays are used to damage cancer cells and stop their growth. Seminomas are highly sensitive to radiation. Nonseminomas are somewhat less responsive to radiation and usually require other types of treatment.

  • chemotherapy – drugs used to kill cancer cells.


The treatment of testicular cancer is determined by the age and health of the patient as well as the stage of the cancer.

Sometimes, for germ cell tumors that are suspected of being more difficult to cure, high dose chemotherapy and autologous stem cell transplantation is used after the initial treatment using standard chemotherapy doses.

Additionally, if the germ cell tumor doesn’t go away (into remission) with the initial chemotherapy, or if it went into remission but recurred, high dose chemotherapy and autologous stem cell transplantation is recommended.



Related Patients & Caregivers Links: THE BASICS, THE PRE-TRANSPLANT PROCESS, PLANNING FOR TRANSPLANT, THE POST-TRANSPLANT PROCESS, THE TRANSPLANT PROCESS
Related News: Causes of male infertility investigated, Testicular cancer and relation to space-time clustering examined, Incidence of leukemia and testicular cancer heightened in persons with Down syndrome in Finland, Testicular cancer incidence increasing and mortality declining in 22 European countries
Related Glossary Terms: Stromal Tumors, Germ Cell Tumors, Radiation Therapy, Lymph Node Biopsy, PET Scan (Positron Emission Tomography), High-Dose Chemotherapy, Chest X - Ray (CXR), Chemotherapy, CAT or CT Scan (Computed Tomography Scan), Biopsy, Autologous Transplant (Auto)
 
RECENT NEWS
 
New Genes Linked to Testicular Cancer Testicular cancer is the most common type of cancer in men ages 15 to 45. The incidence of testicular cancer has been increasing in many western countries. Between 1975 and 2002, the rate of testicular cancer doubled in the United States. The disease responds well to chemotherapy and is highly curable, though many survivors face fertility problems after treatment. Because the disease appears to have a strong genetic component, researchers continue to analyze genetic variants associated with the disease More...
Fewer platelets could be used for some cancer and bone-marrow transplantation patients Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions. More...
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing. More...
Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia Cyclacel Pharmaceuticals, Inc. announced today topline survival data for the primary endpoint of the Phase 2 study of sapacitabine as a treatment for elderly patients aged 70 or older with either newly diagnosed acute myeloid leukemia (AML) or AML in first relapse. The study was a three-arm randomized trial evaluating three dosing schedules of sapacitabine. The primary endpoint of 1-year survival is approximately 30% each on two out of the three schedules tested. Details of the results from this study will be presented at an upcoming medical conference. More...
Second gene linked to familial testicular cancer Specific variations or mutations in a particular can gene raise a man's risk of familial, or inherited, testicular germ-cell cancer, the most common form of this disease, according to new research by scientists at the National Institutes of Health. This is only the second gene to be identified that affects the risk of familial testicular cancer, and the first gene in a key biochemical pathway. The study appears in the July 2009 Cancer Research. More...
 
UPCOMING EVENTS
 
Young Adult Support Group If you are between the ages of 17 and 27 and are coping with cancer or a blood disorder, please join us. More...
Leukemia and Lymphoma Society Family Support Groups Looking for support aournd a diagnosis of Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Myeloma? The Leukemia and Lymphoma Society offers support groups for patients, family members, friends, a. More...
Family Member and Caregiver Support Group A weekly group for family members and caregivers of BMT patients to give and receive support, ask questions, swap ideas, be heard, listen and take a break. More...
 
RECENT CLINICAL TRIALS
 
Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants More...
Treatment of Relapsed or Primary Refractory Hodgkin Lymphoma with High-Dose CBV Followed by Autologous Peripheral Blood Progenitor Cell Rescue More...
1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial More...
1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial More...
1992 - A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia More...
 
RECENT PATIENT STORIES
 
Bob Heykoop "People caring about one another represents life's greatest value." – Jim Rohn More...
Maggie Brunner In the weeks leading up to her transplant, Maggie Brunner and her husband had to ask each other some difficult questions. More...
Leslie Szabo What surprised Leslie most after her transplant was how long it took her to get back to what could be considered a relatively normal life. More...
Janice Gangl Not knowing what was wrong with me for so long was really terrifying. More...
Wayne Marrone "Anything has to be better than sitting on the couch.” More...